Wanted: A new GC for Eli Lilly as Harrington announces retirement
One of the biggest Big Pharma companies will be shopping for a new general counsel. The company is Eli Lillly and Co., and its current GC, Mike Harrington, announced that he’ll be retiring at the end of the year. The company in a statement says that, “Harrington has been a member of Lilly’s executive committee for seven years—a period of strong growth and change for the company.”
According to his company bio, Harrington (in the photo above, courtesy of Lilly) joined Lilly in 1991 after working as a litigator at Baker & Daniels in Indianapolis. The soon-to-be former general counsel is a graduate of Columbia Law School, He’s been on both the business and legal side at Lilly, as managing director of the New Zealand affiliate, associate general counsel for operations in the Asia Pacific region, and vice president and deputy general counsel of global pharmaceutical operations. He was promoted to the GC spot at the start of 2012.
“Thanks to Mike’s leadership, the company maintained patent exclusivity for a number of important medicines, including Alimta®, completed the Elanco divestiture and finalized acquisitions such as Loxo Oncology and ARMO BioSciences,” said David Ricks, Lilly’s chairman and CEO. “But his impact goes far beyond the legal department,” he added. “Mike models the Lilly values, has developed and mentored talent throughout the organization and served as a key advisor to Lilly’s board and two CEOs.”